HOVID-CELECOXIB CAPSULE 200MG

Ülke: Singapur

Dil: İngilizce

Kaynak: HSA (Health Sciences Authority)

Aktif bileşen:

Celecoxib

Mevcut itibaren:

GOLDPLUS UNIVERSAL PTE LTD

ATC kodu:

M01AH01

Farmasötik formu:

CAPSULE

Kompozisyon:

Celecoxib 200 MG

Uygulama yolu:

ORAL

Reçete türü:

Prescription Only

Tarafından üretildi:

Hovid Bhd

Yetkilendirme durumu:

ACTIVE

Yetkilendirme tarihi:

2019-07-26

Ürün özellikleri

HOVID-CELECOXIB CAPSULE 200 MG
VICEL16-var (SIN)
DESCRIPTION
White
opaque/white
opaque
capsule
with
“CL200”
printed on one end and “hovid” printed on the other end
Fill material: white to off white granules
Capsule size: size 0
COMPOSITION
Each capsule contains Celecoxib 200 mg.
Excipients: Lactose monohydrate, dodecyl sulphate
sodium,
polyethylene
glycol,
polyvinylpyrrolidone,
crospovidone, magnesium stearate.
PHARMACODYNAMICS
MECHANISM
OF
ACTION:
Celecoxib
is
an
oral,
selective,
cyclooxygenase-2
(COX-2)
inhibitor
within the clinical dose range (200-400 mg daily). No
statistically significant inhibition of COX-1 (assessed
as _ ex vivo_ inhibition of thromboxane B2 [TxB2]
formation) was observed in this dose range in
healthy volunteers.
PHARMACODYNAMIC
EFFECTS:
Cyclooxygenase
is
responsible for generation of prostagladins. Two
isoforms, COX-1 and COX-2, have been identified.
COX-2 is the isoform of the enzyme that has been
shown to be induced by pro-inflammatory stimuli and
has been postulated to be primarily responsible for
the
synthesis
of
prostanoid
mediators
of
pain,
inflammation, and fever. COX-2 is also involved in
ovulation, implantation and closure of the ductus
arteriosus, regulation of renal function, and central
nervous
system
functions
(fever
induction,
pain
perception and cognitive function). It may also play a
role in ulcer healing. COX-2 has been identified in
tissue
around
gastric
ulcers
in
human
but
its
relevance to ulcer healing has not been established.
The difference in antiplatelet activity between some
COX-1
inhibiting
NSAIDs
and
COX-2
selective
inhibitors may be of clinical significance in patients at
risk of thrombo-embolic reactions. COX-2 selective
inhibitors
reduce
the
formation
of
systemic
(and
therefore possibly endothelial) prostacyclin without
affecting platelet thromboxane.
Celecoxib
is
a
diaryl-substituted
pyrazole,
chemically
similar
to
other
non-arylamine
sulfonamides (e.g. thiazides, furosemide) but differs
from arylamine sulfonamides (e.g. sulfamethoxizole
and other su